Linde plc - First-Quarter 2020 Results + New high-purity nitrogen generator in Shanghai

Linde plc. -   First-Quarter 2020 Results

Linde plc (NYSE: LIN; FWB: LIN)  reported first-quarter 2020 income from continuing operations of $571 million and diluted earnings per share of $1.07. Excluding Linde AG purchase accounting impacts and other charges, adjusted income from continuing operations was $1,009 million, up 9% versus prior year.

Adjusted earnings per share were $1.89, 12% above prior year, or 15% higher when excluding negative currency translation effects. Linde’s sales for the first quarter were $6,739 million, 1% above prior year, excluding negative currency translation and cost pass-through. Price improved 2% and was attained across all geographic segments, but was partially offset by volume decrease of approximately 1% due mainly to the impact of the COVID-19 pandemic.
Quelle und Details: Linde plc Pressemitteilung

U.S. Supreme Court decision - inhaled nitric oxide

Linde is pleased with the decision by the U.S. Supreme Court declining to review the 2019 appeals court decision that affirmed Praxair Distribution, Inc.'s (PDI) right to sell a generic form of inhaled nitric oxide. This decision ends the long-running U.S. patent litigation with Mallinckrodt plc, and affirms the ability of PDI, a wholly owned subsidiary of Linde, to continue supplying inhaled nitric oxide. This drug product is widely used as approved in the U.S. and other countries to improve oxygenation of certain groups of patients.

"Nitric oxide is truly a unique and beneficial drug product. We are proud to be doing our part to support healthcare institutions around the world with a reliable, competitive and beneficial supply of inhaled nitric oxide along with our other medical gases and services," said Ben Glazer, President, US Packaged & Specialty Gases. Linde is actively supporting doctors as they investigate the use of nitric oxide to treat COVID-19 patients globally. This includes supplying nitric oxide to Massachusetts General Hospital to support a trial launched by their researchers to test the drug's effectiveness for preventing disease progression in patients with mild to moderate disease, thereby avoiding the need for ventilation.

Separately, German authorities have authorized on a temporary basis the use of inhaled nitric oxide specifically to treat patients with severe cases of COVID-19.
Quelle und Details: Linde plc Pressemitteilung

New Linde high-purity nitrogen generator in Shanghai

Linde Unternehmen

Das Linde Unternehmen beschäftigt weltweit ca. 80.000 Mitarbeiter und serviciert Kunden in über 100 Ländern der Erde.

"Linde verfolgt eine zentrale Vision: das weltweit stärkste Industriegase- und Engineering-Unternehmen zu sein, unsere Kunden mit innovativen, nachhaltigen Lösungen zu unterstützen und für unsere Stakeholder Mehrwert zu generieren".

Investoren

Financial reports

Linde plc ist sowohl an der New York Stock Exchange als auch an der Frankfurter Börse (Prime Standard) notiert. Das Tickersymbol lautet LIN. So können Linde- Aktien ganz nach Wunsch des Anlegers an beiden Börsenplätzen gehandelt werden. Die CUSIP-Nummer von Linde plc ist G5494J 103, die ISIN ist IE00BZ12WP82

Linde AG

ISIN: IE00BZ12WP82
CUSIP: G5494J 103
Kürzel: LIN

Indizes Börse frankfurt

DAX
Euro Stoxx 50
S&P 500
HDAX (Performance)
Prime All Share (Performance)

Stammdaten Linde AG

Supersektor: Basic Materials
Sektor: Chemicals
Subsektor: Industrial Gases

Externe Links

Linde group website
Börse Frankfurt Linde

Foto: Linde Hydrogen
Quelle & Copyright: Linde

Linde Hydrogen

Twitter share button